Based on the provided data, I would recommend a SELL for Sun Pharmaceutical Industries Limited. Here's my chain of thought:

1. **Valuation**: The trailing PE of 36.48 is relatively high compared to the industry average. While a high PE can be justified by strong growth prospects, the forward PE of 50.85 suggests that the market expects even higher growth, which may be challenging to achieve given the company's current performance.

2. **Profitability**: The ROE of 15.71% is decent, but the profit margin of 20.79% is relatively low compared to industry peers. This could indicate that the company operates on thin margins, leaving little room for error.

3. **Growth**: The revenue growth rate of 8.1% is modest, and the earnings growth rate of -18.8% is a significant concern. This suggests that the company is struggling to translate revenue growth into earnings growth, which may be a sign of underlying issues.

4. **Leverage**: The debt-to-equity ratio of 3.26 is relatively high, indicating that the company has significant debt obligations. This increases the risk of default and may limit the company's ability to invest in growth opportunities.

Considering these factors, I believe that the stock is overvalued and may not be able to justify its current price in the near term. Therefore, I would recommend a SELL.